{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:46:57Z","timestamp":1793666817834,"version":"4.5.1"},"reference-count":110,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671031"],"award-info":[{"award-number":["81671031"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470721"],"award-info":[{"award-number":["81470721"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Science and Technology Program","doi-asserted-by":"publisher","award":["2019YFS0400"],"award-info":[{"award-number":["2019YFS0400"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CSCR"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec><jats:title\/><jats:p>Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease are very harmful brain lesions. Due to the difficulty in obtaining therapeutic drugs, the best treatment for neurodegenerative diseases is often not available. In addition, the bloodbrain barrier can effectively prevent the transfer of cells, particles and macromolecules (such as drugs) in the brain, resulting in the failure of the traditional drug delivery system to provide adequate cellular structure repair and connection modes, which are crucial for the functional recovery of neurodegenerative diseases. Nanomaterials are designed to carry drugs across the blood-brain barrier for targets. Nanotechnology uses engineering materials or equipment to interact with biological systems at the molecular level to induce physiological responses through stimulation, response and target site interactions, while minimizing the side effects, thus revolutionizing the treatment and diagnosis of neurodegenerative diseases. Some magnetic nanomaterials play a role as imaging agents or nanoprobes for Magnetic Resonance Imaging to assist in the diagnosis of neurodegenerative diseases. Although the current research on nanomaterials is not as useful as expected in clinical applications, it achieves a major breakthrough and guides the future development direction of nanotechnology in the application of neurodegenerative diseases. This review briefly discusses the application and advantages of nanomaterials in neurodegenerative diseases. Data for this review were identified by searches of PubMed, and references from relevant articles published in English between 2015 and 2019 using the search terms \u201cnanomaterials\u201d, \u201cneurodegenerative diseases\u201d and \u201cblood-brain barrier\u201d.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1574888x15666200326093410","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T11:48:37Z","timestamp":1585223317000},"page":"83-94","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Application of Nanomaterials in Neurodegenerative Diseases"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7511-3582","authenticated-orcid":true,"given":"Weitong","family":"Cui","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1546-2684","authenticated-orcid":true,"given":"Wei","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Lin","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6200-4603","authenticated-orcid":true,"given":"Tianxu","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102937","volume":"19","author":"Kritsilis M.V.","year":"2018","unstructured":"Kritsilis M.V.; Rizou S.; Koutsoudaki P.N.; Evangelou K.; Gorgoulis V.G.; Papadopoulos D.; Ageing, cellular senescence and neurodegenerative disease. Int J Mol Sci 2018,19(10)","journal-title":"Int J Mol Sci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1021\/acs.nanolett.8b03644","volume":"19","author":"Zhao Y.","year":"2019","unstructured":"Zhao Y.; Cai J.; Liu Z.; Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of \u03b2-amyloid aggregates in Alzheimer\u2019s disease mice. Nano Lett 2019,19(2),674-683","journal-title":"Nano Lett"},{"key":"ref=3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020412","volume":"7","author":"Daneman R.","year":"2015","unstructured":"Daneman R.; Prat A.; The blood-brain barrier. Cold Spring Harb Perspect Biol 2015,7(1)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=4","author":"Furtado D","unstructured":"Furtado D; Bjornmalm M; Ayton S; Bush AI; Kempe K; Caruso F; Overcoming the blood-brain barrier: The role of nanomaterials in treating neurological diseases. Advanced materials: (Deerfield Beach, Fla) 2018; 30(46): e1801362."},{"key":"ref=5","author":"Huo S","unstructured":"Huo S; Li H; Boersma AJ; Herrmann A; .DNA nanotechnology enters cell membranes. advanced science. Weinheim, Baden-Wurttemberg, Germany 2019; 6: p. (10): 1900043. http:\/\/dx.doi.org\/10.1002\/advs.201900043"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-47754-1_1","volume":"947","author":"Atluri R.","year":"2017","unstructured":"Atluri R.; Jensen K.A.; Engineered Nanomaterials: Their Physicochemical Characteristics and How to Measure Them. Adv Exp Med Biol 2017,947,3-23","journal-title":"Adv Exp Med Biol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.yrtph.2017.10.019","volume":"92","author":"Rasmussen K.","year":"2018","unstructured":"Rasmussen K.; Rauscher H.; Mech A.; Physico-chemical properties of manufactured nanomaterials - Characterisation and relevant methods. An outlook based on the OECD Testing Programme. Regul Toxicol Pharmacol 2018,92,8-28","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-981-10-7572-8_8","volume":"1052","author":"Singh M.R.","year":"2018","unstructured":"Singh M.R.; Application of metallic nanomaterials in nanomedicine. Adv Exp Med Biol 2018,1052,83-102","journal-title":"Adv Exp Med Biol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.copbio.2017.01.006","volume":"44","author":"Stover P.J.","year":"2017","unstructured":"Stover P.J.; Durga J.; Field M.S.; Folate nutrition and blood-brain barrier dysfunction. Curr Opin Biotechnol 2017,44,146-152","journal-title":"Curr Opin Biotechnol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/B978-0-444-63432-0.00003-7","volume":"133","author":"Obermeier B.","year":"2016","unstructured":"Obermeier B.; Verma A.; Ransohoff R.M.; The blood-brain barrier. Handb Clin Neurol 2016,133,39-59","journal-title":"Handb Clin Neurol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semcdb.2015.01.002","volume":"38","author":"Serlin Y.","year":"2015","unstructured":"Serlin Y.; Shelef I.; Knyazer B.; Friedman A.; Anatomy and physiology of the blood-brain barrier. Semin Cell Dev Biol 2015,38,2-6","journal-title":"Semin Cell Dev Biol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.brainres.2016.04.024","volume":"1642","author":"Rahman N.A.","year":"2016","unstructured":"Rahman N.A.; Rasil A.N.H.M.; Meyding-Lamade U.; Immortalized endothelial cell lines for in vitro blood-brain barrier models: A systematic review. Brain Res 2016,1642,532-545","journal-title":"Brain Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","volume":"7","author":"Abbott N.J.","year":"2006","unstructured":"Abbott N.J.; R\u00f6nnb\u00e4ck L.; Hansson E.; Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006,7(1),41-53","journal-title":"Nat Rev Neurosci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"Abbott N.J.","year":"2010","unstructured":"Abbott N.J.; Patabendige A.A.; Dolman D.E.; Yusof S.R.; Begley D.J.; Structure and function of the blood-brain barrier. Neurobiol Dis 2010,37(1),13-25","journal-title":"Neurobiol Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.vph.2016.11.008","volume":"89","author":"Chakraborty A.","year":"2017","unstructured":"Chakraborty A.; de Wit N.M.; van der Flier W.M.; de Vries H.E.; The blood brain barrier in Alzheimer\u2019s disease. Vascul Pharmacol 2017,89,12-18","journal-title":"Vascul Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s12035-015-9672-6","volume":"54","author":"Patching S.G.","year":"2017","unstructured":"Patching S.G.; Glucose transporters at the blood-brain barrier: Function, regulation and gateways for drug delivery. Mol Neurobiol 2017,54(2),1046-1077","journal-title":"Mol Neurobiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1515\/revneuro-2016-0071","volume":"28","author":"Pozhilenkova E.A.","year":"2017","unstructured":"Pozhilenkova E.A.; Lopatina O.L.; Komleva Y.K.; Salmin V.V.; Salmina A.B.; Blood-brain barrier-supported neurogenesis in healthy and diseased brain. Rev Neurosci 2017,28(4),397-415","journal-title":"Rev Neurosci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/1389450118666170612100750","volume":"19","author":"Jakki S.L.","year":"2018","unstructured":"Jakki S.L.; Senthil V.; Yasam V.R.; Chandrasekar M.J.N.; Vijayaraghavan C.; The blood brain barrier and its role in Alzheimer\u2019s Therapy: An Overview. Curr Drug Targets 2018,19(2),155-169","journal-title":"Curr Drug Targets"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-180098","volume":"63","author":"Cai Z.","year":"2018","unstructured":"Cai Z.; Qiao P.F.; Wan C.Q.; Cai M.; Zhou N.K.; Li Q.; Role of blood-brain barrier in Alzheimer\u2019s Disease. J Alzheimers Dis 2018,63(4),1223-1234","journal-title":"J Alzheimers Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/0271678X16629976","volume":"37","author":"Haley M.J.","year":"2017","unstructured":"Haley M.J.; Lawrence C.B.; The blood-brain barrier after stroke: Structural studies and the role of transcytotic vesicles. J Cereb Blood Flow Metab 2017,37(2),456-470","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=21","author":"Tsou YH","unstructured":"Tsou YH; Zhang XQ; Zhu H; Syed S; Xu X; Drug delivery to the brain across the blood-brain barrier using nanomaterials Small. Weinheim an der Bergstrasse, Germany 2017; 13(43). http:\/\/dx.doi.org\/10.1002\/smll.201701921","journal-title":"Drug delivery to the brain across the blood-brain barrier using nanomaterials"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","volume":"13","author":"Pardridge W.M.","year":"2016","unstructured":"Pardridge W.M.; CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv 2016,13(7),963-975","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2016.1153568","volume":"4","author":"Grabrucker A.M.","year":"2016","unstructured":"Grabrucker A.M.; Ruozi B.; Belletti D.; Nanoparticle transport across the blood brain barrier. Tissue Barriers 2016,4(1)","journal-title":"Tissue Barriers"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s10787-018-0468-y","volume":"26","author":"Nair K.G.S.","year":"2018","unstructured":"Nair K.G.S.; Ramaiyan V.; Sukumaran S.K.; Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis. Inflammopharmacology 2018,26(3),675-684","journal-title":"Inflammopharmacology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.brainres.2008.01.039","volume":"1200","author":"Wilson B.","year":"2008","unstructured":"Wilson B.; Samanta M.K.; Santhi K.; Kumar K.P.; Paramakrishnan N.; Suresh B.; Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer\u2019s disease. Brain Res 2008,1200,159-168","journal-title":"Brain Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.2147\/IJN.S149022","volume":"13","author":"Ramanathan S.","year":"2018","unstructured":"Ramanathan S.; Archunan G.; Sivakumar M.; Theranostic applications of nanoparticles in neurodegenerative disorders. Int J Nanomedicine 2018,13,5561-5576","journal-title":"Int J Nanomedicine"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s13311-016-0487-6","volume":"14","author":"Vucic S.","year":"2017","unstructured":"Vucic S.; Kiernan M.C.; Transcranial magnetic stimulation for the assessment of neurodegenerative disease. Neurotherapeutics 2017,14(1),91-106","journal-title":"Neurotherapeutics"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1242\/dmm.030205","volume":"10","author":"Gitler A.D.","year":"2017","unstructured":"Gitler A.D.; Dhillon P.; Shorter J.; Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech 2017,10(5),499-502","journal-title":"Dis Model Mech"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a023622","volume":"9","author":"Seeley W.W.","year":"2017","unstructured":"Seeley W.W.; Mapping neurodegenerative disease onset and progression. Cold Spring Harb Perspect Biol 2017,9(8)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/978-3-319-57193-5_18","volume":"15","author":"Veldsman M.","year":"2017","unstructured":"Veldsman M.; Egorova N.; Advances in Neuroimaging for Neurodegenerative Disease. Adv Neurobiol 2017,15,451-478","journal-title":"Adv Neurobiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"16962","DOI":"10.1039\/C8NR04073G","volume":"10","author":"Poovaiah N.","year":"2018","unstructured":"Poovaiah N.; Davoudi Z.; Peng H.; Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers. Nanoscale 2018,10(36),16962-16983","journal-title":"Nanoscale"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.12779\/dnd.2019.18.2.33","volume":"18","author":"Kim S.H.","year":"2019","unstructured":"Kim S.H.; Noh M.Y.; Kim H.J.; K-ARPI. A therapeutic strategy for alzheimer\u2019s disease focused on immune-inflammatory modulation. Dement Neurocognitive Disord 2019,18(2),33-46","journal-title":"Dement Neurocognitive Disord"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s12035-014-9053-6","volume":"53","author":"Kamat P.K.","year":"2016","unstructured":"Kamat P.K.; Kalani A.; Rai S.; Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of alzheimer\u2019s disease: understanding the therapeutics strategies. Mol Neurobiol 2016,53(1),648-661","journal-title":"Mol Neurobiol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1007\/s12035-019-01695-6","volume":"56","author":"Guti\u00e9rrez I.L.","year":"2019","unstructured":"Guti\u00e9rrez I.L.; Gonz\u00e1lez-Prieto M.; Caso J.R.; Garc\u00eda-Bueno B.; Leza J.C.; Madrigal J.L.M.; Reboxetine treatment reduces neuroinflammation and neurodegeneration in the 5xFAD mouse model of alzheimer\u2019s disease: Role of CCL2. Mol Neurobiol 2019,56(12),8628-8642","journal-title":"Mol Neurobiol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"Lane C.A.","year":"2018","unstructured":"Lane C.A.; Hardy J.; Schott J.M.; Alzheimer\u2019s disease. Eur J Neurol 2018,25(1),59-70","journal-title":"Eur J Neurol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1021\/acschemneuro.9b00183","volume":"10","author":"Vilasi S.","year":"2019","unstructured":"Vilasi S.; Carrotta R.; Ricci C.; Inhibition of Abeta1-42 fibrillation by chaperonins: human Hsp60 is a stronger inhibitor than its bacterial homologue GroEL. ACS Chem Neurosci 2019,10(8),3565-3574","journal-title":"ACS Chem Neurosci"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00391-019-01580-w","volume":"52","author":"Heupel-Reuter M.","year":"2019","unstructured":"Heupel-Reuter M.; Kloppel S.; Bauer J.M.; Voigt-Radloff S.; Pharmacological interventions for apathy in Alzheimer\u2019s disease. Zeitschrift fur Gerontologie und Geriatrie 2019,52(5),457-459","journal-title":"Zeitschrift fur Gerontologie und Geriatrie"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"10056","DOI":"10.1038\/s41598-019-46558-1","volume":"9","author":"Ibrahim W.W.","year":"2019","unstructured":"Ibrahim W.W.; Abdelkader N.F.; Ismail H.M.; Khattab M.M.; Escitalopram Ameliorates Cognitive Impairment in D-Galactose-Injected Ovariectomized Rats: Modulation of JNK, GSK-3\u03b2, and ERK Signalling Pathways. Sci Rep 2019,9(1),10056","journal-title":"Sci Rep"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1136\/jnnp-2018-320199","volume":"90","author":"Jia J.","year":"2019","unstructured":"Jia J.; Hu J.; Huo X.; Miao R.; Zhang Y.; Ma F.; Effects of vitamin D supplementation on cognitive function and blood A\u03b2-related biomarkers in older adults with Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry 2019,90(12),1347-1352","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.12779\/dnd.2019.18.2.62","volume":"18","author":"Kang M.J.","year":"2019","unstructured":"Kang M.J.; Kim S.M.; Han S.E.; Effect of paper-based cognitive training in early stage of alzheimer\u2019s dementia. Dement Neurocognitive Disord 2019,18(2),62-68","journal-title":"Dement Neurocognitive Disord"},{"key":"ref=41","author":"Bernard K","unstructured":"Bernard K; Gouttefangeas S; Bretin S; Galtier S; Robert P.; .A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms. Alzheimer's & dementia (New York, N Y) 2019; 5: 231-40."},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/jnc.14079","volume":"143","author":"Tse K.H.","year":"2017","unstructured":"Tse K.H.; Herrup K.; Re-imagining Alzheimer\u2019s disease - the diminishing importance of amyloid and a glimpse of what lies ahead. J Neurochem 2017,143(4),432-444","journal-title":"J Neurochem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature20814","volume":"541","author":"Qiang W.","year":"2017","unstructured":"Qiang W.; Yau W.M.; Lu J.X.; Collinge J.; Tycko R.; Structural variation in amyloid-\u03b2 fibrils from Alzheimer\u2019s disease clinical subtypes. Nature 2017,541(7636),217-221","journal-title":"Nature"},{"key":"ref=44","author":"Rajasekhar K","unstructured":"Rajasekhar K; Chakrabarti M; Govindaraju T; Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease Chemical communications (Cambridge,England) 2015; 51(70): 13434-50. http:\/\/dx.doi.org\/10.1039\/C5CC05264E","journal-title":"Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201801407","volume":"63","author":"Wang Y.","year":"2019","unstructured":"Wang Y.; Guan X.; Chen X.; Choline supplementation ameliorates behavioral deficits and alzheimer\u2019s disease-like pathology in transgenic APP\/PS1 Mice. Mol Nutr Food Res 2019,63(18)","journal-title":"Mol Nutr Food Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3233\/JAD-161088","volume":"57","author":"T\u00f6nnies E.","year":"2017","unstructured":"T\u00f6nnies E.; Trushina E.; Oxidative stress, synaptic dysfunction, and alzheimer\u2019s disease. J Alzheimers Dis 2017,57(4),1105-1121","journal-title":"J Alzheimers Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.tibtech.2017.06.002","volume":"35","author":"Hajipour M.J.","year":"2017","unstructured":"Hajipour M.J.; Santoso M.R.; Rezaee F.; Aghaverdi H.; Mahmoudi M.; Perry G.; Advances in alzheimer\u2019s diagnosis and therapy: The implications of nanotechnology. Trends Biotechnol 2017,35(10),937-953","journal-title":"Trends Biotechnol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1021\/jacs.8b01641","volume":"140","author":"Li Y.","year":"2018","unstructured":"Li Y.; Li Y.; Ji W.; Positively charged polyprodrug amphiphiles with enhanced drug loading and reactive oxygen species-responsive release ability for traceable synergistic therapy. J Am Chem Soc 2018,140(11),4164-4171","journal-title":"J Am Chem Soc"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/s41467-018-04255-z","volume":"9","author":"Luo Q.","year":"2018","unstructured":"Luo Q.; Lin Y.X.; Yang P.P.; A self-destructive nanosweeper that captures and clears amyloid \u03b2-peptides. Nat Commun 2018,9(1),1802","journal-title":"Nat Commun"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"36695","DOI":"10.1021\/acsami.7b13328","volume":"9","author":"Li Q.","year":"2017","unstructured":"Li Q.; Zhao D.; Shao X.; Aptamer-modified tetrahedral DNA Nanostructure for Tumor-Targeted Drug Delivery. ACS Appl Mater Interfaces 2017,9(42),36695-36701","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12368","volume":"50","author":"Shi S.","year":"2017","unstructured":"Shi S.; Lin S.; Shao X.; Li Q.; Tao Z.; Lin Y.; Modulation of chondrocyte motility by tetrahedral DNA nanostructures. Cell Prolif 2017,50(5)","journal-title":"Cell Prolif"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"18402","DOI":"10.1039\/C7NR07130B","volume":"9","author":"Tian T.","year":"2017","unstructured":"Tian T.; Zhang T.; Zhou T.; Lin S.; Shi S.; Lin Y.; Synthesis of an ethyleneimine\/tetrahedral DNA nanostructure complex and its potential application as a multi-functional delivery vehicle. Nanoscale 2017,9(46),18402-18412","journal-title":"Nanoscale"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"32017","DOI":"10.1021\/acsami.8b12408","volume":"10","author":"Lin S.","year":"2018","unstructured":"Lin S.; Zhang Q.; Zhang T.; Tetrahedral DNA nanomaterial regulates the biological behaviors of adipose-derived stem cells via DNA Methylation on Dlg3. ACS Appl Mater Interfaces 2018,10(38),32017-32025","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"7892","DOI":"10.1021\/acsami.8b00833","volume":"10","author":"Ma W.","year":"2018","unstructured":"Ma W.; Shao X.; Zhao D.; Self-assembled tetrahedral dna nanostructures promote neural stem cell proliferation and neuronal differentiation. ACS Appl Mater Interfaces 2018,10(9),7892-7900","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12503","volume":"51","author":"Ma W.","year":"2018","unstructured":"Ma W.; Xie X.; Shao X.; Tetrahedral DNA nanostructures facilitate neural stem cell migration via activating RHOA\/ROCK2 signalling pathway. Cell Prolif 2018,51(6)","journal-title":"Cell Prolif"},{"key":"ref=56","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12511","volume":"52","author":"Liu M.","year":"2019","unstructured":"Liu M.; Ma W.; Li Q.; Aptamer-targeted DNA nanostructures with doxorubicin to treat protein tyrosine kinase 7-positive tumours. Cell Prolif 2019,52(1)","journal-title":"Cell Prolif"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"23682","DOI":"10.1021\/acsami.8b07827","volume":"10","author":"Shao X.","year":"2018","unstructured":"Shao X.; Ma W.; Xie X.; Neuroprotective effect of tetrahedral dna nanostructures in a cell model of Alzheimer\u2019s Disease. ACS Appl Mater Interfaces 2018,10(28),23682-23692","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=58","author":"Shi S","unstructured":"Shi S; Lin S; Li Y; Zhang T; Shao X.; Effects of tetrahedral DNA nanostructures on autophagy in chondrocytes Chemical communications (Cambridge, England) 2018; 54(11): 1327-30.","journal-title":"Effects of tetrahedral DNA nanostructures on autophagy in chondrocytes"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1021\/acsami.7b17928","volume":"10","author":"Zhang Q.","year":"2018","unstructured":"Zhang Q.; Lin S.; Shi S.; Anti-inflammatory and antioxidative effects of tetrahedral DNA Nanostructures via the modulation of macrophage responses. ACS Appl Mater Interfaces 2018,10(4),3421-3430","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1021\/acs.nanolett.8b02166","volume":"18","author":"Zhang Y.","year":"2018","unstructured":"Zhang Y.; Ma W.; Zhu Y.; Inhibiting Methicillin-Resistant Staphylococcus aureus by Tetrahedral DNA nanostructure-enabled antisense peptide nucleic acid delivery. Nano Lett 2018,18(9),5652-5659","journal-title":"Nano Lett"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"37911","DOI":"10.1021\/acsami.8b16518","volume":"10","author":"Zhao D.","year":"2018","unstructured":"Zhao D.; Liu M.; Li Q.; Tetrahedral DNA nanostructure promotes endothelial cell proliferation, migration, and angiogenesis via notch signaling pathway. ACS Appl Mater Interfaces 2018,10(44),37911-37918","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.nano.2018.02.004","volume":"14","author":"Zhou M.","year":"2018","unstructured":"Zhou M.; Liu N.X.; Shi S.R.; Effect of tetrahedral DNA nanostructures on proliferation and osteo\/odontogenic differentiation of dental pulp stem cells via activation of the notch signaling pathway. Nanomedicine (Lond) 2018,14(4),1227-1236","journal-title":"Nanomedicine (Lond)"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1021\/acsami.8b20530","volume":"11","author":"Mao C.","year":"2019","unstructured":"Mao C.; Pan W.; Shao X.; The clearance effect of tetrahedral dna nanostructures on senescent human dermal fibroblasts. ACS Appl Mater Interfaces 2019,11(2),1942-1950","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1039\/C7NR09692E","volume":"10","author":"Xie X.","year":"2018","unstructured":"Xie X.; Shao X.; Ma W.; Overcoming drug-resistant lung cancer by paclitaxel loaded tetrahedral DNA nanostructures. Nanoscale 2018,10(12),5457-5465","journal-title":"Nanoscale"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"27588","DOI":"10.1021\/acsami.9b09243","volume":"11","author":"Ge Y.","year":"2019","unstructured":"Ge Y.; Tian T.; Shao X.R.; Lin S.Y.; PEGylated protamine-based adsorbing improves the biological properties and stability of tetrahedral framework nucleic acids. ACS Appl Mater Interfaces 2019,11(31),27588-27597","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=66","author":"Liu N","unstructured":"Liu N; Zhang X; Li N; Zhou M; Zhang T; Tetrahedral framework nucleic acids promote corneal epithelial wound healing in vitro and in vivo Small (Weinheim an der Bergstrasse, Germany) 2019; e1901907.","journal-title":"Tetrahedral framework nucleic acids promote corneal epithelial wound healing in vitro and in vivo"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1021\/acsami.8b22444","volume":"11","author":"Meng L.","year":"2019","unstructured":"Meng L.; Ma W.; Lin S.; Shi S.; Li Y.; Lin Y.; Tetrahedral DNA nanostructure-delivered DNAzyme for gene silencing to suppress cell growth. ACS Appl Mater Interfaces 2019,11(7),6850-6857","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12566","volume":"52","author":"Zhou M.","year":"2019","unstructured":"Zhou M.; Liu N.; Zhang Q.; Effect of tetrahedral DNA nanostructures on proliferation and osteogenic differentiation of human periodontal ligament stem cells. Cell Prolif 2019,52(3)","journal-title":"Cell Prolif"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.biomaterials.2013.09.063","volume":"35","author":"Zhang C.","year":"2014","unstructured":"Zhang C.; Wan X.; Zheng X.; Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer\u2019s disease mice. Biomaterials 2014,35(1),456-465","journal-title":"Biomaterials"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11682-017-9745-4","volume":"13","author":"Xuan M.","year":"2019","unstructured":"Xuan M.; Guan X.; Huang P.; Different patterns of gray matter density in early- and middle-late-onset Parkinson\u2019s disease: A voxel-based morphometry study. Brain Imaging Behav 2019,13(1),172-179","journal-title":"Brain Imaging Behav"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10571-019-00649-9","volume":"39","author":"Filippini A.","year":"2019","unstructured":"Filippini A.; Gennarelli M.; Russo I.; \u03b1-Synuclein and glia in Parkinson\u2019s disease: A beneficial or a detrimental duet for the endo-lysosomal system? Cell Mol Neurobiol 2019,39(2),161-168","journal-title":"Cell Mol Neurobiol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s11682-018-9863-7","volume":"13","author":"Chondrogiorgi M.","year":"2019","unstructured":"Chondrogiorgi M.; Astrakas L.G.; Zikou A.K.; Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson\u2019s disease patients. Brain Imaging Behav 2019,13(1),232-240","journal-title":"Brain Imaging Behav"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.intimp.2018.11.004","volume":"66","author":"Zhu Y.L.","year":"2019","unstructured":"Zhu Y.L.; Sun M.F.; Jia X.B.; Neuroprotective effects of Astilbin on MPTP-induced Parkinson\u2019s disease mice: Glial reaction, \u03b1-synuclein expression and oxidative stress. Int Immunopharmacol 2019,66,19-27","journal-title":"Int Immunopharmacol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuroscience.2017.10.050","volume":"403","author":"Haghshomar M.","year":"2019","unstructured":"Haghshomar M.; Rahmani F.; Hadi Aarabi M.; Shahjouei S.; Sobhani S.; Rahmani M.; White matter changes correlates of peripheral neuroinflammation in patients with Parkinson\u2019s Disease. Neuroscience 2019,403,70-78","journal-title":"Neuroscience"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/ene.13797","volume":"26","author":"Chahine L.M.","year":"2019","unstructured":"Chahine L.M.; Dos Santos C.; Fullard M.; Modifiable vascular risk factors, white matter disease and cognition in early Parkinson\u2019s disease. Eur J Neurol 2019,26(2),246-e18","journal-title":"Eur J Neurol"},{"key":"ref=76","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2019.108574","volume":"176","author":"Calder\u00f3n-Garcidue\u00f1as L.","year":"2019","unstructured":"Calder\u00f3n-Garcidue\u00f1as L.; Reynoso-Robles R.; Gonz\u00e1lez-Maciel A.; Combustion and friction-derived nanoparticles and industrial-sourced nanoparticles: The culprit of Alzheimer and Parkinson\u2019s diseases. Environ Res 2019,176","journal-title":"Environ Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/psyg.12366","volume":"19","author":"Dogan B.","year":"2019","unstructured":"Dogan B.; Akyol A.; Memis C.O.; Sair A.; Akyildiz U.; Sevincok L.; The relationship between temperament and depression in Parkinson\u2019s disease patients under dopaminergic treatment. Psychogeriatrics 2019,19(1),73-79","journal-title":"Psychogeriatrics"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/10717544.2019.1636420","volume":"26","author":"Tang S.","year":"2019","unstructured":"Tang S.; Wang A.; Yan X.; Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson\u2019s disease. Drug Deliv 2019,26(1),700-707","journal-title":"Drug Deliv"},{"key":"ref=79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118449","volume":"\u2022","author":"Gan L.","year":"2019","unstructured":"Gan L.; Li Z.; Lv Q.; Huang W.; Rabies virus glycoprotein (RVG29)-linked microRNA-124-loaded polymeric nanoparticles inhibit neuroinflammation in a Parkinson\u2019s disease model. Int J Pharm 2019,\u2022","journal-title":"Int J Pharm"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.msec.2019.03.086","volume":"101","author":"Girigoswami A.","year":"2019","unstructured":"Girigoswami A.; Ramalakshmi M.; Akhtar N.; Metkar S.K.; Girigoswami K.; ZnO Nanoflower petals mediated amyloid degradation - An in vitro electrokinetic potential approach. Mater Sci Eng C 2019,101,169-178","journal-title":"Mater Sci Eng C"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1021\/acssensors.9b00182","volume":"4","author":"Xiao G.","year":"2019","unstructured":"Xiao G.; Song Y.; Zhang Y.; Microelectrode arrays modified with nanocomposites for monitoring dopamine and spike firings under deep brain stimulation in rat models of Parkinson\u2019s Disease. ACS Sens 2019,4(8),1992-2000","journal-title":"ACS Sens"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.brainres.2019.05.040","volume":"1719","author":"Yu S.J.","year":"2019","unstructured":"Yu S.J.; Wang Y.C.; Chang C.Y.; NanoCsA improves the survival of human iPSC transplant in hemiparkinsonian rats. Brain Res 2019,1719,124-132","journal-title":"Brain Res"},{"key":"ref=83","doi-asserted-by":"publisher","author":"Ahlawat J","unstructured":"Ahlawat J; Deemer EM; Narayan M; Chitosan Nanoparticles Rescue Rotenone-Mediated Cell Death.Materials. Basel, Switzerland 2019; 12: (7).","DOI":"10.3390\/ma12071176"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1176\/jnp.15.1.109","volume":"15","author":"Huntington G.","year":"2003","unstructured":"Huntington G.; On chorea. George Huntington, M.D. J Neuropsychiatry Clin Neurosci 2003,15(1),109-112","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"Walker F.O.","year":"2007","unstructured":"Walker F.O.; Huntington\u2019s disease. Lancet 2007,369(9557),218-228","journal-title":"Lancet"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"Pringsheim T.","year":"2012","unstructured":"Pringsheim T.; Wiltshire K.; Day L.; Dykeman J.; Steeves T.; Jette N.; The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis. Mov Disord 2012,27(9),1083-1091","journal-title":"Mov Disord"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","year":"1993","unstructured":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell The Huntington\u2019s Disease Collaborative Research Group1993,72(6),971-983","journal-title":"Cell"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.2174\/0929867326666190621101909","volume":"27","author":"Tellone E.","year":"2020","unstructured":"Tellone E.; Galtieri A.; Ficarra S.; Reviewing the biochemical implications of normal and mutated huntingtin in Huntington\u2019s disease. Curr Med Chem 2020,27(31),5137-5158","journal-title":"Curr Med Chem"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/stem.277","volume":"28","author":"Lee J.K.","year":"2010","unstructured":"Lee J.K.; Jin H.K.; Endo S.; Schuchman E.H.; Carter J.E.; Bae J.S.; Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer\u2019s disease mice by modulation of immune responses. Stem Cells 2010,28(2),329-343","journal-title":"Stem Cells"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","year":"2006","unstructured":"Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology Huntington Study Group2006,66(3),366-372","journal-title":"Neurology"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1471-2377-9-62","volume":"9","author":"Frank S.","year":"2009","unstructured":"Frank S.; Tetrabenazine as anti-chorea therapy in Huntington disease: An open-label continuation study. BMC Neurol Huntington Study Group\/TETRA-HD Investigators2009,9,62","journal-title":"BMC Neurol"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5334\/tohm.129","volume":"3","author":"Shen V.","year":"2013","unstructured":"Shen V.; Clarence-Smith K.; Hunter C.; Jankovic J.; Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with huntington\u2019s and other diseases. Tremor Other Hyperkinet Mov (N Y) 2013,3,3","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1021\/mp3003946","volume":"10","author":"Godinho B.M.","year":"2013","unstructured":"Godinho B.M.; Ogier J.R.; Darcy R.; O\u2019Driscoll C.M.; Cryan J.F.; Self-assembling modified \u03b2-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington\u2019s disease. Mol Pharm 2013,10(2),640-649","journal-title":"Mol Pharm"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"24126","DOI":"10.1021\/acsami.7b06510","volume":"9","author":"Debnath K.","year":"2017","unstructured":"Debnath K.; Pradhan N.; Singh B.K.; Jana N.R.; Jana N.R.; Poly(trehalose) nanoparticles prevent amyloid aggregation and suppress polyglutamine aggregation in a huntington\u2019s disease model mouse. ACS Appl Mater Interfaces 2017,9(28),24126-24139","journal-title":"ACS Appl Mater Interfaces"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1021\/acschemneuro.8b00545","volume":"10","author":"Joshi A.S.","year":"2019","unstructured":"Joshi A.S.; Singh V.; Gahane A.; Thakur A.K.; Biodegradable nanoparticles containing mechanism based peptide inhibitors reduce polyglutamine aggregation in cell models and alleviate motor symptoms in a drosophila model of Huntington\u2019s Disease. ACS Chem Neurosci 2019,10(3),1603-1614","journal-title":"ACS Chem Neurosci"},{"key":"ref=96","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119248","volume":"216","author":"Zhang L.","year":"2019","unstructured":"Zhang L.; Wei P.F.; Song Y.H.; MnFe2O4 nanoparticles accelerate the clearance of mutant huntingtin selectively through ubiquitin-proteasome system. Biomaterials 2019,216","journal-title":"Biomaterials"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1021\/jacs.8b11441","volume":"141","author":"Ceccon A.","year":"2019","unstructured":"Ceccon A.; Tugarinov V.; Clore G.M.; TiO2 nanoparticles catalyze oxidation of huntingtin Exon 1-derived peptides impeding aggregation: A quantitative NMR study of binding and kinetics. J Am Chem Soc 2019,141(1),94-97","journal-title":"J Am Chem Soc"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12017-013-8261-y","volume":"16","author":"Sandhir R.","year":"2014","unstructured":"Sandhir R.; Yadav A.; Mehrotra A.; Sunkaria A.; Singh A.; Sharma S.; Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington\u2019s disease. Neuromolecular Med 2014,16(1),106-118","journal-title":"Neuromolecular Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cbi.2016.05.020","volume":"256","author":"Ramachandran S.","year":"2016","unstructured":"Ramachandran S.; Thangarajan S.; A novel therapeutic application of solid lipid nanoparticles encapsulated thymoquinone (TQ-SLNs) on 3-nitroproponic acid induced Huntington\u2019s disease-like symptoms in wistar rats. Chem Biol Interact 2016,256,25-36","journal-title":"Chem Biol Interact"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s11011-018-0252-0","volume":"33","author":"Ramachandran S.","year":"2018","unstructured":"Ramachandran S.; Thangarajan S.; Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington\u2019s disease. Metab Brain Dis 2018,33(5),1459-1470","journal-title":"Metab Brain Dis"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3109\/10717544.2014.880860","volume":"22","author":"Bhatt R.","year":"2015","unstructured":"Bhatt R.; Singh D.; Prakash A.; Mishra N.; Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington\u2019s disease. Drug Deliv 2015,22(7),931-939","journal-title":"Drug Deliv"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.15252\/emmm.201505413","volume":"7","author":"Valenza M.","year":"2015","unstructured":"Valenza M.; Chen J.Y.; Di Paolo E.; Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington\u2019s disease mice. EMBO Mol Med 2015,7(12),1547-1564","journal-title":"EMBO Mol Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/cdd.2014.162","volume":"22","author":"Valenza M.","year":"2015","unstructured":"Valenza M.; Marullo M.; Di Paolo E.; Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington\u2019s disease. Cell Death Differ 2015,22(4),690-702","journal-title":"Cell Death Differ"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ijpharm.2018.03.061","volume":"543","author":"Belletti D.","year":"2018","unstructured":"Belletti D.; Grabrucker A.M.; Pederzoli F.; Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain. Int J Pharm 2018,543(1-2),300-310","journal-title":"Int J Pharm"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.brainres.2018.11.034","volume":"1707","author":"Liu X.G.","year":"2019","unstructured":"Liu X.G.; Lu S.; Liu D.Q.; ScFv-conjugated superparamagnetic iron oxide nanoparticles for MRI-based diagnosis in transgenic mouse models of Parkinson\u2019s and Huntington\u2019s diseases. Brain Res 2019,1707,141-153","journal-title":"Brain Res"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.scr.2012.05.005","volume":"9","author":"Moraes L.","year":"2012","unstructured":"Moraes L.; Vasconcelos-dos-Santos A.; Santana F.C.; Neuroprotective effects and magnetic resonance imaging of mesenchymal stem cells labeled with SPION in a rat model of Huntington\u2019s disease. Stem Cell Res (Amst) 2012,9(2),143-155","journal-title":"Stem Cell Res (Amst)"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2019.02.031","volume":"300","author":"Kaviarasi S.","year":"2019","unstructured":"Kaviarasi S.; Yuba E.; Harada A.; Krishnan U.M.; Emerging paradigms in nanotechnology for imaging and treatment of cerebral ischemia. J Control Release 2019,300,22-45","journal-title":"J Control Release"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.bbrc.2019.06.079","volume":"516","author":"Huang L.","year":"2019","unstructured":"Huang L.; Wang J.; Huang S.; Siaw-Debrah F.; Nyanzu M.; Zhuge Q.; Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke. Biochem Biophys Res Commun 2019,516(2),565-570","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=109","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.05.020","volume":"215","author":"Mei T.","year":"2019","unstructured":"Mei T.; Kim A.; Vong L.B.; Encapsulation of tissue plasminogen activator in pH-sensitive self-assembled antioxidant nanoparticles for ischemic stroke treatment - Synergistic effect of thrombolysis and antioxidant. Biomaterials 2019,215","journal-title":"Biomaterials"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.2147\/IJN.S193965","volume":"14","author":"So P.W.","year":"2019","unstructured":"So P.W.; Ekonomou A.; Galley K.; Intraperitoneal delivery of acetate-encapsulated liposomal nanoparticles for neuroprotection of the penumbra in a rat model of ischemic stroke. Int J Nanomedicine 2019,14,1979-1991","journal-title":"Int J Nanomedicine"}],"container-title":["Current Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/180513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/180513\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/180513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T20:18:43Z","timestamp":1666210723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/180513\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574888x15666200326093410","relation":{},"ISSN":["1574-888X"],"issn-type":[{"value":"1574-888X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}